[Cite as http://purl.org/au-research/grants/nhmrc/1073768]
Brief description Impaired development of blood stem cells leads to haematological disease such as leukaemia. State of the art next-generation sequencing and bioinformatics identified molecular pathways essential for normal blood development and a core set of these genes repressed in leukaemia. Understanding the mechanism by which these genes are re-activated by the non-specific drug azacitidine contributes to the development of new therapeutics with increased efficiency and reduced side effects.
Funding Amount $AUD 316,449.66
Funding Scheme Early Career Fellowships
Peter Doherty Biomedical ECF